Evidence map›Paper›PMID 41606710›Full record

ReviewChemistry (Weinheim an der Bergstrasse, Germany)2026

Catalytic Amyloids: Turning Fibrils Into Biocatalysts.

Alessandra Esposito, Linda Leone, Flavia Nastri, Angela Lombardi

Abstract readReview
In one paragraph

Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alessandra EspositoDepartment of Chemical Sciences, University of Napoli Federico II, Napoli, Italy.ORCID https://orcid.org/0009-0007-7099-6359
Linda LeoneDepartment of Chemical Sciences, University of Napoli Federico II, Napoli, Italy.ORCID https://orcid.org/0000-0001-7293-1814
Flavia NastriDepartment of Chemical Sciences, University of Napoli Federico II, Napoli, Italy.ORCID https://orcid.org/0000-0002-3390-9822
Angela LombardiDepartment of Chemical Sciences, University of Napoli Federico II, Napoli, Italy.ORCID https://orcid.org/0000-0002-2013-3009

Funding

European Research Council CUPE68D190017100006Ministero dell'Università e della Ricerca CUP: E63C22003710006National Recovery and Resilience Plan (NRRP), European Union - NextGenerationEU CUPE63C22002160007Università degli Studi di Napoli Federico II project title: "HyByBio"
6 · The paper itself

Abstract

Amyloids have been regarded as the pathological entities behind neurodegenerative diseases for a long time. The discovery that they also play physiological roles together with their ability to form stable and ordered scaffolds opened the door for their applications in different fields. In this context, catalytic amyloids have emerged as a new class of nanomaterials, merging the efficiency of enzymes with the robustness of heterogeneous catalysts. Indeed, these systems exploit the self-assembly properties of amyloids while mimicking enzymatic functions by exposing catalytic moieties on their surface. In this review, we first provide an overview of the structural and functional properties of natural amyloids and their application in nanotechnology. Then, we survey the current state of art in the development of catalytic amyloids, based on bioinspired or de novo designed sequences. In both cases, the incorporation of specific functional groups provides the fibrils with catalytic functions. Finally, we illustrate the use of amyloid fibrils as platforms for enzyme immobilization. All the selected examples highlight the power of bridging amyloid structures and catalytic activities to shape innovative nanomaterials toward demanding needs.

Indexed as

AmyloidBiocatalysisCatalysisHumansNanostructuresNanotechnologyAmyloidamyloidsbiocatalysismetalloenzymesnanomaterialspeptides

Identifiers

PMID41606710
PMCPMC12995857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.